title: Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy.
abstract: We report a case of septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. This is the first report of septic arthritis due to R. mucosa, and infliximab therapy might be a predisposing factor because this infection was never reported in the pre-anti-tumor necrosis factor alpha therapy period.
authors.affiliation: Pathophysiology Department, Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece.
authors.forename: Nikolaos V
authors.initials: NV
authors.lastname: Sipsas
authors.forename: Joseph
authors.initials: J
authors.lastname: Papaparaskevas
authors.forename: Ioanna
authors.initials: I
authors.lastname: Stefanou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kalatzis
authors.forename: Panayiotis
authors.initials: P
authors.lastname: Vlachoyiannopoulos
authors.forename: Athina
authors.initials: A
authors.lastname: Avlamis
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001170:Arthritis, Infectious / Q000276:immunology / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000276:immunology / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008297:Male; D042082:Methylobacteriaceae / Q000235:genetics; D008969:Molecular Sequence Data
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab